iShares MSCI Australia ETF vs Roivant Sciences Ltd. Common Shares — how do they compare? iShares MSCI Australia ETF trades at $28.27 (market cap $1.19B), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 21.1× iShares MSCI Australia ETF's market cap, and Roivant Sciences Ltd. Common Shares is more actively traded (5,738,571 versus 2,714,198). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 63 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| EWA | ROIV | |
|---|---|---|
Market Cap | $1.19B | $25.09B |
Volume | 2,714,198 | 5,738,571 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $41.81 |
52-Week Low | $24.95 | $16.04 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | — | $21.36B |
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Australia ETF (EWA) trades at $28.23, down 1.12% amid bearish technical signals and mixed institutional activity. Recent news highlights Australia's stock market hitting three-month lows due to inflation concerns from rising oil prices, though some analysts see upside potential given the country's commodity-driven economy. Technical indicators show selling pressure with moving averages signaling bearish momentum while oscillators remain neutral.
EWA faces near-term headwinds from Australian market volatility and inflation worries, but long-term prospects remain tied to global commodity demand. The ETF's commodity exposure provides diversification benefits, though investors should monitor Australian economic conditions and Federal Reserve policy impacts. Risk-reward appears balanced with technical resistance at $29 and support at $28.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →